Clinical trial · Observational
Assessment of the Prevalence of Sarcopenia in Early Palliative Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cancer is one of the leading causes of death in the world after cardiovascular disease (8.7 million deaths in 2015 for 17.5 million cases) 1. Despite a great deal of progress in disease detection and treatment, the incidence of cancer is steadily increasing (+ 33% in 2015) and particularly in certain locations (pancreas, lungs, brain and stomach), including risk factors are not always identified. Advanced stage cancer (= metastatic) is most often incurable with the exception of germ cell tumors. Palliative care is then most often offered. Palliative care favors the patient's quality of life as a whole (medical, physical, psychological and social). The symptoms most often reported by patients are: pain, fatigue, decreased appetite, nausea, and are directly related to phenomena such as cachexia, loss of autonomy and deterioration of psychological state, resulting in decreased overall survival. Chemotherapies and targeted therapies (immunotherapy, hormonal therapy, participation in a clinical trial) can provide a benefit in quality of life and survival only in the early phase (little benefit in the terminal phase). Other prognostic factors can impact the quality of life and overall survival in these situations: sarcopenia and disorders of nutritional status (obesity, undernutrition). The study of sarcopenia by CT scan of patients in a palliative situation is still too scarce. Sarcopenia is an often underestimated event and is associated with older age, co-morbidities, increased infectious complications, and early mortality. The study of the prevalence of sarcopenia by CT scan would confirm its prognostic impact in a palliative situation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| sarcopenia assessment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- cohort
- description
- Sarcopenia assessment
- interventionNames
- Other: sarcopenia assessment
Primary outcomes (1)
- measure
- Prevalence of sarcopenia
- timeFrame
- 1 month
- description
- Number of patients with sarcopenia in the numerator out of the total number of patients included in the study in the denominator
Secondary outcomes (5)
- measure
- Prevalence of undernutrition
- timeFrame
- 1 month
- description
- Number of patients with nutritional disorders at inclusion in numerator out of the number of patients followed in denominator
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * age\> 18 years old, * patient with solid cancer diagnosed with metastatic disease, * having had a biological assessment and a CT scan in the month preceding the medical consultation, * and whose prognosis is considered palliative Exclusion Criteria: * age \<18 years old, * adults under guardianship measure, * pregnancy or breastfeeding in progress, * malignant hemopathies, * metastatic germ cell tumors, * non-metastatic disease
References
Publications (0)
Data not yet available